Johnson & Johnson (JNJ) is in talks to acquire Intra-Cellular Therapies (ITCI), Bloomberg News reported Sunday, citing unnamed people familiar with the matter.
An agreement for an acquisition could be reached as early as this week but the discussions also fall apart and other buyers may emerge, the report said, citing the sources.
Intra-Cellular Therapies develops drugs for mental health disorders and neurological conditions.
Johnson & Johnson and Intra-Cellular Therapies did not immediately reply to MT Newswires' request for comment.
Shares of Intra-Cellular were up more than 32% in Monday's premarket activity.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.